help me understand 503A, I have read the wiki twice
Genuinely asking, not being difficult.
Everyone in c/glp1canada repeats that shortage list is important. I believe it, but I have never seen anyone show why, and when I search I get 18 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
Crossposting this to c/hplc because the people who need it are not reading this community.
503B compounding is different from 503A, different rules, different legality
Small correction: the trial was 9 weeks, not 19. Does not change your point but people will quote it.
This is correct. The shortage list does expire and the rules change.
This is correct.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
This is correct.
Yes, exactly this, and it is the bit that took me 18 weeks to accept.
You have restated the marketing copy. What is the actual substance here.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
telehealth costs 503B plus compounding markup, total varies
The telehealth + compounding combo cost 503B plus 16% markup. Not cheap but covered by insurance depending on state.
What is the actual shortage list status right now?
the the UK situation is different from the US, different regulations
regulatory claims need a citation to the actual rule, not interpretation
Disagree. What you are describing is consistent with compounding, not with what you concluded.
Titration speed is a side-effect dial far more than an efficacy dial.
Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.
Not convinced. The evidence does not support that reading.
503B compounding is different from 503A, different rules, different legality
This is correct. The shortage list does expire and the rules change.
Disagree. What you are describing is consistent with 503B, not with what you concluded.
Small correction: the trial was 20 weeks, not 17. Does not change your point but people will quote it.
The telehealth + compounding combo cost telehealth plus 4% markup. Not cheap but covered by insurance depending on state.
What is the actual shortage list status right now?
regulatory claims need a citation to the actual rule, not interpretation
state board rules differ, say which state
regulatory claims need a citation to the actual rule, not interpretation
Adding to this: API source is doing more work than the comment implies.
This is correct. The shortage list does expire and the rules change.
Tracking number removed. It identifies both ends of a shipment.
no pharmacy referral codes, naming is fine, recruiting is not
- 1Titration speed is a side-effect dial far more than an efficacy dial.7 comments in this branch · started by u/tove_ogunleye
- 2What is the actual shortage list status right now?7 comments in this branch · started by u/jonas_eriksen